List of Excipients in Branded Drug NEOPROFEN

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Recordati Rare Diseases Inc	NEOPROFEN	ibuprofen lysine	55292-122	WATER

Neoprofen Excipient Strategy and Commercial Opportunities

Last updated: August 31, 2026

Neoprofen is an injectable ibuprofen lysine product approved by the U.S. Food and Drug Administration in 2006 for the closure of clinically significant patent ductus arteriosus in premature infants. Its commercial value depends less on molecular exclusivity than on neonatal formulation safety, sterile manufacturing, supply reliability, hospital procurement, and regulatory execution. The primary opportunity is a differentiated generic or alternative ibuprofen lysine injection with improved vial utilization, stability, packaging, and global distribution.

What is Neoprofen and how is it formulated?

Neoprofen contains ibuprofen lysine, a water-soluble salt of ibuprofen. The product is administered intravenously to premature infants for patent ductus arteriosus. The labeled regimen consists of an initial dose followed by two additional doses at 24-hour intervals, subject to clinical and laboratory assessment.[1]

The product is supplied as a sterile, preservative-free injectable solution. The formulation uses excipients that support solubility, isotonicity, pH control, and parenteral tolerability. The U.S. labeling identifies arginine, sodium chloride, hydrochloric acid, and water for injection among the formulation components.[1]

Attribute	Neoprofen
Active ingredient	Ibuprofen lysine
Therapeutic area	Neonatal patent ductus arteriosus
Dosage form	Sterile injectable solution
Route	Intravenous
Patient population	Premature infants
U.S. approval	2006
NDA	021706
Preservative status	Preservative-free
Main formulation requirements	Solubility, pH control, osmolality, sterility, low particulate burden
Product type	Small-molecule drug
Biosimilar pathway	Not applicable

The neonatal setting imposes tighter formulation constraints than most adult injectable products. Excipients must have an acceptable safety profile for premature infants, including low exposure to preservatives, buffers, surfactants, residual solvents, extractables, and leachables.

What excipients are used in Neoprofen?

The labeled excipient system is designed to maintain ibuprofen lysine in solution while providing a suitable injectable environment. Arginine supports formulation pH and may contribute to solubility. Sodium chloride adjusts tonicity. Hydrochloric acid controls pH. Water for injection is the vehicle.[1]

The commercial importance of each excipient is as follows:

Excipient or component	Functional role	Commercial and technical consideration
Arginine	Solubility and pH support	Must meet injectable-grade specifications; source qualification is important
Sodium chloride	Tonicity adjustment	Affects osmolality and neonatal tolerability
Hydrochloric acid	pH adjustment	Requires tight control during compounding
Water for injection	Vehicle	Requires validated sterile water system and endotoxin control
Container closure system	Product protection	Must control adsorption, extractables, leachables, and vial integrity

The formulation has a relatively limited excipient profile. That reduces toxicological complexity but increases the importance of process control. Small changes in pH, concentration, ionic strength, or sterilization conditions can affect precipitation, particulate formation, assay, and stability.

What excipient strategy is most attractive for a Neoprofen competitor?

The strongest strategy is to preserve the basic excipient architecture while improving product usability and manufacturing robustness. A completely new excipient system would create additional neonatal safety and regulatory risk without necessarily providing a meaningful clinical benefit.

Preservative-free ready-to-use formulation

A preservative-free, ready-to-use solution is commercially attractive because neonatal intensive-care units seek to minimize manipulation of injectable products. A finished product that can be withdrawn directly from the vial may reduce preparation steps, compounding burden, and contamination risk.

The product would need validated in-use stability after vial entry, particularly if the full vial is not administered to a single patient. A single-dose vial remains the most conservative regulatory and clinical presentation, but it can create substantial wastage because neonatal doses are small.

Low-waste concentration and vial configuration

The standard opportunity is not necessarily a higher-strength product. A better commercial design may use vial sizes that align with neonatal dosing and reduce discarded product. Potential presentations include:

• A smaller single-dose vial for low-weight infants.
• A larger vial for institutions with predictable daily volume.
• A unit-dose hospital pack.
• A dual-size package containing different vial volumes.
• A ready-to-administer syringe, if stability and device compatibility are demonstrated.

The tradeoff is manufacturing complexity. Multiple vial sizes increase packaging, inventory, and quality-control costs. A smaller vial may command a premium if it materially reduces wastage and nursing time.

Improved pH and osmolality control

A competitor could seek a tighter pH and osmolality profile than the reference product, but these improvements would need to translate into measurable benefits. The relevant targets are:

• Reduced precipitation after dilution or preparation.
• Lower variability between lots.
• Improved compatibility with infusion components.
• Reduced particulate formation.
• Better stability under refrigerated and controlled-room-temperature conditions.

The evidence package would need to distinguish formulation improvement from ordinary manufacturing control. A generic product generally cannot rely on broad formulation claims that are not supported by comparative pharmaceutical data.

Alternative buffer systems

Alternative buffers such as phosphate, citrate, acetate, or tromethamine could be evaluated, but neonatal use makes this a high-risk path. Buffer selection affects pH drift, osmolality, calcium compatibility, precipitation behavior, and systemic exposure.

An alternative buffer could support a differentiated product if it produces a documented advantage, such as longer stability or reduced dilution requirements. The same change could also create a new regulatory burden because the product would no longer be a straightforward formulation copy.

Lyophilized ibuprofen lysine

A lyophilized presentation could improve long-term stability and reduce sensitivity to transport conditions. It would require a validated reconstitution step and an appropriate diluent. That may reduce the convenience advantage compared with a ready-to-use solution.

A lyophilized product is most attractive in markets where cold-chain reliability is weak or where extended shelf life has high procurement value. In U.S. neonatal hospitals, the added preparation step may limit adoption unless the liquid product has meaningful supply or stability problems.

What patents protect Neoprofen?

Neoprofen's central exclusivity was based on regulatory status and the underlying ibuprofen lysine technology rather than a durable, high-value biologic patent estate. The product is a small-molecule injectable, so it does not receive patent protection associated with biologic manufacturing cell lines or biosimilar reference-product exclusivity.

The FDA approved Neoprofen under NDA 021706 in 2006.[1] The product received orphan-drug exclusivity for the approved neonatal indication. Seven-year orphan exclusivity would have expired in 2013, assuming no intervening regulatory extension.[2]

Exclusivity category	Neoprofen status
U.S. NDA approval	2006
Orphan-drug exclusivity	Expired after the statutory seven-year period
New chemical entity exclusivity	Not the principal commercial barrier
Pediatric exclusivity	No current commercial effect
Biosimilar exclusivity	Not applicable
Small-molecule generic pathway	ANDA pathway generally relevant
Patent-driven barrier	Requires current Orange Book and patent-record review

The current commercial analysis should separate three issues:

1. Patent expiry for any listed formulation, method-of-use, or manufacturing patents.
2. FDA regulatory exclusivity, which is separate from patent term.
3. Practical barriers, including sterile injectable capacity, neonatal data requirements, and hospital contracting.

A patent covering a new excipient combination, vial configuration, stability profile, or administration method would not automatically block a conventional ibuprofen lysine injection. Its value would depend on claim scope, validity, infringement exposure, and whether the claimed feature is commercially necessary.

What is the Orange Book status of Neoprofen?

Neoprofen is an FDA-approved small-molecule product and is therefore evaluated through the Orange Book framework applicable to approved drug products. The relevant listing is the reference product associated with NDA 021706.[3]

A commercial entrant should verify:

• Whether the reference product has active listed patents.
• Whether any listed patents cover the formulation, method of use, or product presentation.
• Whether the listed patents have expired or are subject to pediatric extensions.
• Whether the reference product is currently marketed.
• Whether an ANDA applicant would need a Paragraph IV certification.
• Whether the product is eligible for a 505(j) ANDA or would require a 505(b)(2) application.

A conventional ibuprofen lysine injection with the same active ingredient, strength, route, dosage form, and essential formulation characteristics is more likely to pursue the ANDA route. A materially different formulation, new delivery device, new concentration, or new clinical use could push the product toward a 505(b)(2) strategy.

When did Neoprofen lose exclusivity?

Neoprofen's orphan-drug exclusivity would have ended approximately seven years after its October 2006 approval, placing the end of that period in 2013.[1,2] Any patent protection must be analyzed separately because patent terms depend on the specific patent, terminal disclaimers, patent-term adjustment, and pediatric extension.

The practical result is that a competitor's entry risk is primarily determined by:

• The current patent record.
• FDA approval requirements.
• Availability of sterile injectable manufacturing.
• Product supply continuity.
• Hospital purchasing behavior.
• The ability to demonstrate pharmaceutical equivalence or a clinically acceptable alternative.

Are there Paragraph IV challenges to Neoprofen?

A Paragraph IV challenge is possible if an ANDA applicant identifies an unexpired listed patent and asserts that the patent is invalid, unenforceable, or not infringed. The commercial impact would depend on whether the reference product has active Orange Book-listed patents at the time of filing.

No Paragraph IV litigation should be inferred solely from the existence of Neoprofen or its historical orphan designation. A reliable challenge assessment requires a current review of FDA Orange Book listings, ANDA litigation records, and federal court dockets.

For this product, the likely risk hierarchy is:

Risk	Assessment
Biosimilar competition	Not applicable
Conventional generic injection	High strategic feasibility
Formulation-specific patent litigation	Dependent on current listings
Method-of-use litigation	Narrower, because the use is a defined neonatal indication
Manufacturing-process litigation	Usually difficult to detect and enforce against an ANDA
Hospital substitution	High if a therapeutically equivalent product is approved

What formulation patents could protect a Neoprofen competitor?

The most defensible patent opportunities would focus on technical features that are difficult to design around and commercially valuable. Potential claim categories include:

Stability and precipitation control

Claims could cover a defined ibuprofen lysine concentration, pH range, osmolality range, storage condition, and impurity profile. These claims require robust data showing that the combination produces an unexpected stability benefit.

Low-waste packaging

A patent could cover a vial volume, fill volume, dose-extraction configuration, or packaging system designed for premature infants. The claim would be stronger if it reduced measurable product wastage across representative neonatal dosing bands.

Ready-to-administer delivery

A prefilled syringe or closed-system transfer device could support device and formulation claims. Compatibility with infusion lines, syringe materials, and sterilization processes would be central to the technical package.

Lyophilized dosage form

A lyophilized ibuprofen lysine composition could be protected through formulation, cake structure, residual moisture, reconstitution time, and stability claims. Commercial value would depend on whether the added reconstitution step is acceptable to hospitals.

Manufacturing controls

Process claims could address sterilization, compounding sequence, filtration, filling, and particulate control. These claims often provide weaker market exclusion than composition claims because competitors may use different processes.

What commercial opportunities exist for Neoprofen excipients?

The largest opportunities are formulation-adjacent rather than raw-excipient sales. Arginine, sodium chloride, hydrochloric acid, and water for injection are established materials with limited standalone pricing power. Value is created through qualified supply, injectable-grade documentation, and integration into a reliable finished product.

Potential opportunities include:

Opportunity	Buyer	Value driver
Finished generic ibuprofen lysine injection	Hospitals, group purchasing organizations	Lower acquisition cost and supply competition
Smaller vial presentation	Neonatal intensive-care units	Reduced wastage
Ready-to-use syringe	Hospitals	Lower preparation burden
Alternative global presentation	International distributors	Cold-chain and local procurement fit
Contract manufacturing	Generic pharmaceutical companies	Access to sterile injectable capacity
Excipient supply package	Product developers	Qualified, validated neonatal-grade materials
Stability-enhanced formulation	Brand or specialty manufacturers	Longer shelf life and fewer stockouts
Hospital-specific packaging	Institutional buyers	Workflow integration

Supply reliability may be as important as price. Sterile injectable shortages can create rapid switching opportunities, but hospitals will prioritize FDA compliance, continuity of supply, and pharmacy confidence over minor formulation differences.

How does Neoprofen compare with competing PDA treatments?

Neoprofen competes primarily with indomethacin and acetaminophen-based approaches for patent ductus arteriosus management. The commercial comparison is clinical and operational rather than based on excipient novelty.

Product category	Active ingredient	Key commercial issue
Neoprofen	Ibuprofen lysine	Injectable neonatal product with established FDA indication
Indomethacin injection	Indomethacin	Established PDA therapy; renal and gastrointestinal considerations affect use
Acetaminophen	Acetaminophen	Alternative medical management in selected settings; often different regulatory and clinical positioning
Surgical or catheter closure	Not a drug	Procedural alternative for selected patients

A lower-cost ibuprofen lysine product could compete effectively if it matches the reference product on dosing, stability, presentation, and hospital workflow. A differentiated excipient strategy is unlikely to displace the reference product by itself. It must improve handling, reduce wastage, or solve a supply problem.

What generic entry risks exist for Neoprofen?

Generic entry risk is structurally high because the active ingredient is a known small molecule and the indication is narrow. The main barriers are not discovery science. They are sterile manufacturing, pediatric formulation control, bioequivalence strategy, quality documentation, and commercial scale.

The most credible launch scenarios are:

1. A conventional ANDA product with the same concentration and a comparable excipient profile.
2. A lower-waste vial presentation supported by a 505(b)(2) or another differentiated regulatory strategy.
3. A contract-manufactured product launched by a specialty generic company.
4. A regional product focused on markets with limited access to neonatal ibuprofen injection.
5. A supply-continuity product positioned around manufacturing redundancy rather than premium clinical differentiation.

Revenue exposure for the incumbent depends on the size of the neonatal PDA market, hospital purchasing contracts, pricing, and the number of approved competitors. The narrow patient population limits absolute sales potential, but hospital products can support attractive margins when competition is limited and supply reliability is high.

What manufacturing and geographic barriers affect the opportunity?

The principal manufacturing barrier is sterile injectable capability. A successful competitor needs validated aseptic processing, terminal sterilization assessment, low-bioburden control, container-closure integrity testing, and particulate control.

Geographic opportunities are strongest where:

• Premature birth rates create substantial neonatal intensive-care demand.
• Imported injectable products face supply interruptions.
• Local sterile manufacturing capacity is limited.
• Hospitals use centralized procurement.
• Regulatory pathways recognize U.S. or European quality documentation.

The same formulation may require different vial labeling, concentration conventions, dosing instructions, and packaging sizes by jurisdiction. A global strategy should avoid unnecessary excipient changes because each change can create additional stability and regulatory work.

Key Takeaways

• Neoprofen is ibuprofen lysine injection for premature infants with patent ductus arteriosus.
• Its labeled excipients include arginine, sodium chloride, hydrochloric acid, and water for injection.
• Orphan-drug exclusivity from the 2006 approval would have expired in 2013.
• Biosimilar competition is irrelevant because Neoprofen is a small-molecule drug.
• The most attractive commercial opportunities are generic entry, lower-waste vial sizes, ready-to-use delivery, and supply-continuity positioning.
• A preservative-free solution with strong stability and low particulate burden is the lowest-risk formulation strategy.
• Alternative buffers and lyophilized products offer potential differentiation but increase regulatory and manufacturing complexity.
• Patent value is likely to center on specific formulation, packaging, stability, or delivery claims rather than broad ibuprofen lysine composition claims.
• The main barriers are sterile manufacturing, neonatal safety requirements, hospital procurement, and product reliability.

FAQs

Can arginine be replaced in a Neoprofen-type formulation?

Yes, but replacing arginine would require a new assessment of solubility, pH, osmolality, stability, particulate formation, extractables, and neonatal safety. The change could also affect the regulatory pathway.

Is a Neoprofen prefilled syringe commercially viable?

A prefilled syringe could reduce pharmacy preparation and dosing errors. Its viability depends on syringe-material compatibility, extractables and leachables, stability, sterility assurance, and acceptable fill-volume economics.

Would a smaller Neoprofen vial support patent protection?

A smaller vial could support packaging or use-related claims if it produces a measurable reduction in wastage or improves neonatal dosing workflow. A simple change in vial size alone would generally provide limited patent strength.

Could a lyophilized ibuprofen lysine product compete with Neoprofen?

Yes. Lyophilization could improve stability and transport flexibility, but reconstitution requirements may reduce adoption in neonatal intensive-care units that prefer ready-to-use injections.

Is Neoprofen exposed to biosimilar substitution?

No. Biosimilars apply to biological products. Ibuprofen lysine is a small molecule, so competition would generally involve generic or alternative small-molecule injectable products.

References

1. U.S. Food and Drug Administration. (2016). NeoProfen (ibuprofen lysine) injection prescribing information.
2. U.S. Food and Drug Administration. (n.d.). Orphan drug designation and exclusivity.
3. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book.